Search
Fosinoprilat
go.drugbank.com/drugs/DB14207ExperimentalFosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.
Categories: Agents Acting on the Renin-Angiotensin SystemHemoglobin
go.drugbank.com/drugs/DB04945ApprovedInvestigationalWithdrawnThe respiratory protein of the red blood cells. It consists primarily of globin and heme.
Topiroxostat
go.drugbank.com/drugs/DB01685InvestigationalTopiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases [A19657]. … Renal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended.
m-Chlorophenylpiperazine
go.drugbank.com/drugs/DB12110Investigationalm-Chlorophenylpiperazine has been used in trials studying the treatment of Alcoholism.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeChloride ion
go.drugbank.com/drugs/DB14547InvestigationalMixtures: PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1000 ML, PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1500 MLRosin
go.drugbank.com/drugs/DB11165ApprovedIt is prepared from heating fresh liquid resin to vaporize the volatile liquid terpene components. … Rosin has shown to mediate antibacterial actions on Gram-positive bacterial species [A27267].
Lyme disease vaccine (recombinant OspA)
go.drugbank.com/drugs/DB00045ApprovedWithdrawnLipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant.
Aminocaproic acid
go.drugbank.com/drugs/DB00513ApprovedInvestigationalAn antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
International brands: E-CaproMixtures: Relief and Nature Toothpast E Jasmine MintBrecanavir
go.drugbank.com/drugs/DB04887InvestigationalIn December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug. … In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007.